Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive, Phase 2, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease

NCT06015841 is registered in ClinicalTrials.gov with AC Immune SA as lead sponsor.

NCT NCT06015841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06015841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive, Phase 2, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease
Lead sponsor
AC Immune SA
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 24, 2023
Completion date
June 30, 2028
Enrollment
150 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease, parkinson disease 6, early-onset